Epigral Share News - Latest Updates, Live News & More

Latest news about Epigral

Epigral Limited Receives EcoVadis Silver Medal for Sustainability Excellence Feb 03, 2026

Epigral Limited has been awarded the EcoVadis Silver Medal on February 3, 2026, placing the integrated chemical manufacturer in the top 15% of over 150,000 companies globally assessed for sustainability. The recognition spans four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. Chairman Maulik Patel highlighted that this achievement reflects the company's deep integration of sustainability into business strategy and operations at its Dahej facility in Gujarat.

Epigral Limited Publishes Q3 FY26 Results: Revenue Declines 7.5% YoY to ₹597.12 Crore Jan 31, 2026

Epigral Limited Schedules Conference Call for Q3FY26 Results Discussion on January 30, 2026 Jan 23, 2026

Epigral Limited Receives ₹52.52 Crore Tax Assessment Order and Demand Notice Jan 01, 2026

Epigral Q2 FY26: Revenue Dips 4% to Rs 589 Cr Despite Volume Growth Nov 14, 2025

More news about Epigral

11Nov 25

Epigral Anticipates Stronger Performance in H2 FY26 Despite Q2 Revenue Dip

Epigral Limited reported Q2 FY26 financial results with revenue of ₹589.10 crore, down 7% year-on-year. EBITDA stood at ₹132.00 crore with a 23% margin, while net profit decreased by 36% to ₹51.52 crore. The company faced challenges due to extended monsoons, affecting demand and realizations. Plant utilization improved to 78% from 73% in the previous quarter. Ongoing expansion projects for CPVC and Epichlorohydrin capacities are progressing as scheduled, with commissioning expected in H1 FY27. Management expects improved performance in H2 FY26 as monsoon season ends and maintenance work completes.

10Nov 25

Epigral Limited Reports Strong Q2 Results and Appoints New CFO

Epigral Limited announced its Q2 FY2026 results, reporting revenue of ₹387.36 crores and profit after tax of ₹51.82 crores. The company appointed Mr. Rakesh Agrawal as the new CFO, effective November 10, 2025. Epigral also invested in a renewable energy project, demonstrating commitment to sustainability.

06Aug 25

Epigral Limited Reports 6% Revenue Decline in Q1, Maintains 27% EBITDA Margin

Epigral Limited, a chemical manufacturer, reported a 6% year-on-year revenue decline to INR 615.00 crores in Q1. Despite this, the company maintained its EBITDA margin at 27%. The revenue drop was attributed to lower volumes due to plant maintenance and early monsoon. The company shifted to a new tax regime, resulting in a one-time credit of INR 81.00 crores, boosting PAT to INR 160.00 crores. Epigral's ongoing projects include capacity expansion of CPVC resin and Epichlorohydrin plants, and a wind-solar hybrid power plant. The company expects better performance in the second half of the year and is progressing with its capex projects, anticipating a total capex of INR 450.00 crores for the fiscal year.

05Aug 25

Epigral Anticipates Stronger H2 FY26 Performance, Outlines Rs 450 Crore Capex Plan

Epigral Limited expects a stronger second half in FY26 with projected net debt of Rs 600 crore. The company plans Rs 450 crore CAPEX for FY26, with Rs 120 crore already utilized in Q1. Epigral published Q1 FY26 results, made an earnings call recording available, and scheduled a meeting with New Mark Capital on August 6, 2025, to discuss recent earnings and corporate presentations.

02Aug 25

Epigral Unveils ₹4 Billion Bond Issuance Plan Amid Strong Q1 Performance

Epigral, a leading Indian chemical manufacturer, announces plans to raise up to ₹4 billion through bond issuance. The company's Board has approved the proposal to issue non-convertible debentures, bonds, or other debt securities. This decision follows a robust Q1 performance with revenue of ₹606.54 crore, EBITDA of ₹163 crore (27% margin), and PAT of ₹160.41 crore. Epigral is also progressing with capacity expansion plans for CPVC Resin, Epichlorohydrin, and a new Wind Solar Hybrid Power Plant. The company maintains a strong position in the specialty chemical business, with 50% of Q1 revenue coming from Derivatives and Specialty segments.

02Aug 25

Epigral Limited Reports Strong Q1 Results, Plans Rs 400 Crore Debt Fundraising

Epigral Limited, formerly Meghmani Finechem, reported a significant 86.50% year-on-year increase in Q1 profit after tax to Rs 160.41 crore, despite a 6.86% decrease in revenue. The profit boost was partly due to a one-time tax benefit of Rs 80.87 crore. The company's Board approved plans to raise up to Rs 400 crore through debt securities. Epigral also announced investment in a wind-solar hybrid power project, committing to purchase 51% of the power generated for 20 years.

28Jul 25

Epigral to Discuss Q1 Results and Fundraising Plans in Upcoming Board Meeting

Epigral Limited has scheduled a board meeting for August 2, 2025, to review Q1 financial results and consider fundraising options. The meeting agenda includes examining unaudited financial results for Q1 ended June 30, 2025, and evaluating proposals for raising funds through non-convertible debentures, bonds, or other debt securities. This announcement complies with SEBI regulations.

04Jun 25

Epigral Embraces Green Energy: Signs Agreements for 19.80 MW Wind-Solar Hybrid Power

Epigral has executed two agreements to acquire 19.80 MW of wind-solar hybrid power. This strategic move towards renewable energy sources demonstrates the company's commitment to sustainability and potentially improves its energy security and cost management. The hybrid model, combining wind and solar power, aims to provide a more consistent and reliable energy supply for the company's industrial operations.

06May 25

EPIGRAL Reports Strong FY2025 Performance with 33% Revenue Growth and 82% Jump in Profits

EPIGRAL Limited announced robust financial results for FY2025. Revenue increased by 33% to ₹2,550.13 crore, EBITDA grew 48% to ₹711.00 crore, and net profit surged 82% to ₹357.00 crore. The company's performance was driven by an 11% increase in sales volume, improved capacity utilization, and higher revenue contribution from the Derivatives & Specialty business. EPIGRAL successfully raised ₹333.00 crore through a QIP and commissioned new capacities. The Board proposed a final dividend of ₹3.50 per share, bringing the total dividend for FY2025 to ₹6.00 per share.

05May 25

Epigral Reports Mixed Results: Lower Volume Growth Amid Strong Financial Performance

Epigral Limited announced its FY2025 results, showing robust financial performance despite lower-than-expected volume growth. Revenue increased by 33% to ₹2,565 crore, EBITDA grew 48% to ₹711 crore, and net profit jumped 82% to ₹357 crore. The company's focus on high-value products, particularly in the Derivatives & Specialty segment, contributed significantly to growth. Epigral plans to expand CPVC Resin and Epichlorohydrin capacities, with commissioning expected in H1 FY2027. A final dividend of ₹3.50 per share was proposed, bringing the total FY2025 dividend to ₹6 per share.

05May 25

EPIGRAL Reports Strong Q4 FY2023 Results with Revenue Growth and Dividend Declaration

EPIGRAL announced robust Q4 FY2023 financial results, with revenue increasing 19.62% year-over-year to ₹6,280.00 crore. Net profit grew 12.55% to ₹870.00 crore, while EBITDA slightly improved to ₹1,740.00 crore. However, EBITDA margin decreased from 32.76% to 27.71%. The company declared a dividend of ₹3.50 per share.

24Mar 25

Epigral Pioneers India's First Chlorotoluenes Value Chain Facility

Epigral has successfully commissioned India's first Chlorotoluenes Value Chain Facility at its Dahej location. This facility marks a significant advancement in India's chemical manufacturing capabilities, potentially reducing the country's dependence on imports for these crucial chemical components. The strategic location in Dahej, Gujarat, offers advantages in infrastructure and distribution. This achievement is expected to enhance Epigral's product offerings and market position, while also impacting the broader Indian chemical industry through import substitution, value addition, and technological advancement.